Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Manish Saran

Child & Adolescent Psychiatry Shreveport, LA Medical Doctor

NPI 1821208224 CMS profile 927803

7591 Fern Avenue, Suite 1705, Shreveport, LA 71105

Open in the dashboard

General payments

$11,009

707 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Manish Saran of Shreveport, LA is reported in the CMS Open Payments database as having received $11,009 across 707 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Child & Adolescent Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,195 122
2024 General $2,095 120
2023 General $1,804 107
2022 General $1,481 96
2021 General $1,078 72
2020 General $921 66
2019 General $1,434 124

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Manish Saran
  • Child & Adolescent Psychiatry median
  • Middle half of Child & Adolescent Psychiatry
  • National median

In program year 2025, general payments to Manish Saran were reported at $2,195. Among 1,601 Child & Adolescent Psychiatry profiles paid that year, the median was $132 and the middle half received between $41 and $474.

Show as a table
Year Manish Saran Child & Adolescent Psychiatry median Middle half National median
2019 $1,434 $129 $42–$419 $163
2020 $921 $81 $28–$226 $114
2021 $1,078 $115 $31–$326 $132
2022 $1,481 $124 $40–$382 $149
2023 $1,804 $130 $45–$420 $160
2024 $2,095 $141 $42–$490 $164
2025 $2,195 $132 $41–$474 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Alkermes, Inc. $1,604 86 payments
  2. Sunovion Pharmaceuticals Inc. $1,122 113 payments
  3. Neurocrine Biosciences, Inc. $964 61 payments
  4. Lundbeck LLC $806 52 payments
  5. Teva Pharmaceuticals USA, Inc. $740 47 payments
  6. Otsuka America Pharmaceutical, Inc. $690 42 payments
  7. Takeda Pharmaceuticals U.S.A., Inc. $665 39 payments
  8. ITI, Inc. $627 40 payments
  9. Corium, Inc. $590 30 payments
  10. Janssen Pharmaceuticals, Inc $512 25 payments
  11. Other $2,690 172 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $11,006 706 payments
  2. Education $3 1 payment
Products named General payments · program years 2019–2025
  1. LYBALVI Cns $1,336 71 payments
  2. LATUDA $1,119 112 payments
  3. ARISTADA Cns $1,114 81 payments
  4. ARISTADA Cns $1,114 81 payments
  5. ARISTADA Cns $946 71 payments
  6. ARISTADA Cns $946 71 payments
  7. INGREZZA $788 51 payments
  8. REXULTI Psychiatry $727 46 payments
  9. LYBALVI Cns $657 15 payments
  10. REXULTI Psychiatry $647 39 payments
  11. Other $7,893 428 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 3 drugs

Part D claims

51

Median for Psychiatry: 574

Drug cost

$8,506

Median for Psychiatry: $27,624

Branded share of claims

68.6%

Median for Psychiatry: 17%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 12 $7,652
Ziprasidone Hcl Generic 16 $688
Venlafaxine Hcl Er Venlafaxine Hcl Brand 23 $166

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 20,488 Part D prescribers listed as Psychiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 6 billing codes

Paid by Medicare

$43,557

Medicare's payments for the services billed

Medicare patients

90

Average age 71

Services billed

561

71 women, 19 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Depression 75%
High blood pressure 72%
Arthritis 59%
Osteoporosis 33%
Diabetes 30%
Ischemic heart disease 17%
Chronic kidney disease 13%
COPD 12%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 20 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Azstarys
$255 — —
INGREZZA
$212 — —
REXULTI
$209 — —
INVEGA SUSTENNA
$198 — —
TRINTELLIX
$178 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 20 in the dashboard with a free account

Records

707 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Child & Adolescent Psychiatry in Louisiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record